BIOMAT Database Logo BIOMAT Database Logo

Phase II evaluation of bisantrene in metastatic breast cancer. 1985

F Cavalli, and B Gerard, and W ten Bokkel Huinink, and M Clavel, and M Rozencweig

UI MeSH Term Description Entries
D007958 Leukocyte Count The number of WHITE BLOOD CELLS per unit volume in venous BLOOD. A differential leukocyte count measures the relative numbers of the different types of white cells. Blood Cell Count, White,Differential Leukocyte Count,Leukocyte Count, Differential,Leukocyte Number,White Blood Cell Count,Count, Differential Leukocyte,Count, Leukocyte,Counts, Differential Leukocyte,Counts, Leukocyte,Differential Leukocyte Counts,Leukocyte Counts,Leukocyte Counts, Differential,Leukocyte Numbers,Number, Leukocyte,Numbers, Leukocyte
D009362 Neoplasm Metastasis The transfer of a neoplasm from one organ or part of the body to another remote from the primary site. Metastase,Metastasis,Metastases, Neoplasm,Metastasis, Neoplasm,Neoplasm Metastases,Metastases
D010689 Phlebitis Inflammation of a vein, often a vein in the leg. Phlebitis associated with a blood clot is called (THROMBOPHLEBITIS). Periphlebitis,Periphlebitides,Phlebitides
D001943 Breast Neoplasms Tumors or cancer of the human BREAST. Breast Cancer,Breast Tumors,Cancer of Breast,Breast Carcinoma,Cancer of the Breast,Human Mammary Carcinoma,Malignant Neoplasm of Breast,Malignant Tumor of Breast,Mammary Cancer,Mammary Carcinoma, Human,Mammary Neoplasm, Human,Mammary Neoplasms, Human,Neoplasms, Breast,Tumors, Breast,Breast Carcinomas,Breast Malignant Neoplasm,Breast Malignant Neoplasms,Breast Malignant Tumor,Breast Malignant Tumors,Breast Neoplasm,Breast Tumor,Cancer, Breast,Cancer, Mammary,Cancers, Mammary,Carcinoma, Breast,Carcinoma, Human Mammary,Carcinomas, Breast,Carcinomas, Human Mammary,Human Mammary Carcinomas,Human Mammary Neoplasm,Human Mammary Neoplasms,Mammary Cancers,Mammary Carcinomas, Human,Neoplasm, Breast,Neoplasm, Human Mammary,Neoplasms, Human Mammary,Tumor, Breast
D004341 Drug Evaluation Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals. Evaluation Studies, Drug,Drug Evaluation Studies,Drug Evaluation Study,Drug Evaluations,Evaluation Study, Drug,Evaluation, Drug,Evaluations, Drug,Studies, Drug Evaluation,Study, Drug Evaluation
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000873 Anthracenes A group of compounds with three aromatic rings joined in linear arrangement.

Related Publications

F Cavalli, and B Gerard, and W ten Bokkel Huinink, and M Clavel, and M Rozencweig
Phase II evaluation of Ly156758 in metastatic breast cancer.
January 1988, Oncology,
F Cavalli, and B Gerard, and W ten Bokkel Huinink, and M Clavel, and M Rozencweig
Phase II trial of bisantrene in patients with metastatic melanoma.
August 1986, Cancer treatment reports,
F Cavalli, and B Gerard, and W ten Bokkel Huinink, and M Clavel, and M Rozencweig
Phase II trial of Bisantrene for metastatic melanoma: an Illinois cancer council study.
January 1991, Medical and pediatric oncology,
F Cavalli, and B Gerard, and W ten Bokkel Huinink, and M Clavel, and M Rozencweig
Phase II clinical evaluation of AZQ in metastatic breast cancer.
February 1983, American journal of clinical oncology,
F Cavalli, and B Gerard, and W ten Bokkel Huinink, and M Clavel, and M Rozencweig
Evaluation of bisantrene administered by 72-hour infusion in women with metastatic breast cancer.
October 1986, American journal of clinical oncology,
F Cavalli, and B Gerard, and W ten Bokkel Huinink, and M Clavel, and M Rozencweig
Phase II evaluation of thalidomide in patients with metastatic breast cancer.
July 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
F Cavalli, and B Gerard, and W ten Bokkel Huinink, and M Clavel, and M Rozencweig
Chemotherapy in metastatic melanoma: phase II studies of amsacrine, mitoxantrone and bisantrene.
January 1986, European journal of cancer & clinical oncology,
F Cavalli, and B Gerard, and W ten Bokkel Huinink, and M Clavel, and M Rozencweig
Phase II evaluation of bisantrene in patients with renal cell carcinoma.
October 1982, Cancer treatment reports,
F Cavalli, and B Gerard, and W ten Bokkel Huinink, and M Clavel, and M Rozencweig
Phase II evaluation of piperazinedione in metastatic breast carcinoma.
December 1977, Cancer treatment reports,
F Cavalli, and B Gerard, and W ten Bokkel Huinink, and M Clavel, and M Rozencweig
Phase II evaluation of cisplatin and WR2721 for refractory metastatic breast cancer.
August 1997, American journal of clinical oncology,
Copied contents to your clipboard!